Last Price
26.41
Today's Change
+0.06 (0.22%)
Day's Change
25.68 - 26.96
Trading Volume
436,967
Market Cap
1 Billion
Shares Outstanding
69 Million
Avg Volume
710,751
Avg Price (50 Days)
25.48
Avg Price (200 Days)
22.94
PE Ratio
-7.68
EPS
-3.44
Earnings Announcement
11-Nov-2024
Previous Close
26.35
Open
26.56
Day's Range
25.68 - 26.96
Year Range
11.25 - 53.77
Trading Volume
436,967
1 Day Change
0.23%
5 Day Change
-2.76%
1 Month Change
11.53%
3 Month Change
14.73%
6 Month Change
-14.48%
Ytd Change
12.48%
1 Year Change
-46.98%
3 Year Change
9.54%
5 Year Change
18.06%
10 Year Change
44.16%
Max Change
44.16%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.